BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14(17): 2639-2649 [PMID: 18461649 DOI: 10.3748/wjg.14.2639]
URL: https://www.wjgnet.com/1007-9327/full/v14/i17/2639.htm
Number Citing Articles
1
S.O. Asagba ., G.E. Eriyamremu .. Oral Cadmium Exposure and Levels of Superoxide Dismutase, Catalase, Lipid Peroxidation and ATPases in the EyeResearch Journal of Environmental Toxicology 2007; 1(4): 204 doi: 10.3923/rjet.2007.204.209
2
A. V. Pushkina, E. B. Avalueva, I. G. Bakulin, A. A. Topanova, K. A. Klikunova, I. V. Lapinskii, S. I. Sitkin. Risk factors for various clinical variants of irritable bowel syndromeExperimental and Clinical Gastroenterology 2022; (5): 39 doi: 10.31146/1682-8658-ecg-201-5-39-48
3
S. Bourgoin, A. Gautier, M. Hamon. Le yin et le yang de la sérotonine : un Janus dans les contrôles de la douleurDouleur et Analgésie 2017; 30(1): 35 doi: 10.1007/s11724-017-0486-3
4
Graeme Tobyn, Alison Denham, Margaret Whitelegg. Medical Herbs2011; : 241 doi: 10.1016/B978-0-443-10344-5.00029-X
5
P. M. HELLSTRÖM, J. HEIN, P. BYTZER, E. BJÖRNSSÖN, J. KRISTENSEN, H. SCHAMBYE. Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind studyAlimentary Pharmacology & Therapeutics 2009; 29(2): 198 doi: 10.1111/j.1365-2036.2008.03870.x
6
Reizdarmsyndrom wird immer besser verstandenMMW - Fortschritte der Medizin 2014; 156(19): 60 doi: 10.1007/s15006-014-3643-0
7
Stanislas A. Doffou, Kissi Henriette Anzouan-Kacou, Eugene K. Messou, Demba A. Bangoura, Dimitri H. Kouamé, Kouame M. Alassan, Constant Assi, Fulgence Mamert Y. Bathaix, Alain K. Attia, Marie-Jeanne K. Lohoues. Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)Open Journal of Gastroenterology 2017; 7(10): 261 doi: 10.4236/ojgas.2017.710027
8
Eduardo Esteban-Zubero, Laura López-Pingarrón, Moisés Alejandro Alatorre-Jiménez, Purificación Ochoa-Moneo, Celia Buisac-Ramón, Miguel Rivas-Jiménez, Silvia Castán-Ruiz, Ángel Antoñanzas-Lombarte, Dun-Xian Tan, José Joaquín García, Russel J. Reiter. Melatonin's role as a co-adjuvant treatment in colonic diseases: A reviewLife Sciences 2017; 170: 72 doi: 10.1016/j.lfs.2016.11.031
9
Heraldo A.C. Rocha, Thiago V. Rocha, Fernando J.F. Nóbrega, Liana C.S. Morais, Margareth F.F.M. Diniz. Randomized controlled trial of Panax ginseng in patients with irritable bowel syndromeRevista Brasileira de Farmacognosia 2018; 28(2): 218 doi: 10.1016/j.bjp.2018.02.007
10
B. Bonaz, J.-M. Sabate. Le dysfonctionnement du « brain-gut »Gastroentérologie Clinique et Biologique 2009; 33: S48 doi: 10.1016/S0399-8320(09)71525-8
11
Yu Jin, Yan Lin, Lianjie Lin, Changqing Zheng. IL-17/IFN-γInteractions Regulate Intestinal Inflammation in TNBS-Induced Acute ColitisJournal of Interferon & Cytokine Research 2012; 32(11): 548 doi: 10.1089/jir.2012.0030
12
Xiangping Wang, Yikuan Feng, Jiansheng Li, Zibin Tian, Dong Wei, Lingzhi Qi, Lifeng Fang, Kaichun Wu. Routine clinical administration of 4-week alverine citrate and simeticone combination relief global IBS symptomsOpen Journal of Gastroenterology 2014; 4(01): 32 doi: 10.4236/ojgas.2014.41006
13
Lokesh Agrawal, Mustafa Korkutata, Sunil Kumar Vimal, Manoj Kumar Yadav, Sanjib Bhattacharyya, Takashi Shiga. Therapeutic potential of serotonin 4 receptor for chronic depression and its associated comorbidity in the gutNeuropharmacology 2020; 166: 107969 doi: 10.1016/j.neuropharm.2020.107969
14
Orla F Craig, Eamonn MM Quigley. Bacteria, genetics and irritable bowel syndromeExpert Review of Gastroenterology & Hepatology 2010; 4(3): 271 doi: 10.1586/egh.10.31
15
He Zhu, Xi Xiao, Yuna Chai, Detang Li, Xue Yan, Hongmei Tang. MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7Biochemical and Biophysical Research Communications 2019; 511(3): 671 doi: 10.1016/j.bbrc.2019.02.126
16
H. Mönnikes, S. Müller-Lissner. Funktionelle Magen- und DarmerkrankungenDer Gastroenterologe 2008; 3(5): 415 doi: 10.1007/s11377-008-0224-8
17
L. Chris Sanchez. Equine Internal Medicine2018; : 709 doi: 10.1016/B978-0-323-44329-6.00012-7
18
Robert V. Bryant, Daniel R. van Langenberg, Gerald J. Holtmann, Jane M. Andrews. Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological statusJournal of Gastroenterology and Hepatology 2011; 26(5): 916 doi: 10.1111/j.1440-1746.2011.06624.x
19
Xudan Lei, Zhenni Xu, Lingxiao Huang, Yujun Huang, Siyu Tu, Lu Xu, Dengqun Liu. The potential influence of melatonin on mitochondrial quality control: a reviewFrontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1332567
20
Raish Oozeer, Patrick Veiga. Probiotic Foods in Health and Disease2011; : 75 doi: 10.1201/b10770-9
21
Jinjoo Kim, Kumsun Cho, Joo Sung Kim, Hyun Chae Jung, Bumsik Kim, Myeong Soo Park, Geun Eog Ji, Joo-Youn Cho, Kyoung Sup Hong. Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trialFood Science and Biotechnology 2020; 29(6): 837 doi: 10.1007/s10068-019-00717-2
22
Bo Lian, Louis Vera-Portocarrero, Tamara King, Michael H. Ossipov, Frank Porreca. Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivityBrain Research 2010; 1358: 64 doi: 10.1016/j.brainres.2010.08.032
23
Ning Ma, Jie Zhang, Russel J. Reiter, Xi Ma. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammationMedicinal Research Reviews 2020; 40(2): 606 doi: 10.1002/med.21628
24
Sabine Krüger. Osteopathische Behandlung des Reizdarmsyndroms – ein ReviewOsteopathische Medizin 2016; 17(4): 22 doi: 10.1016/S1615-9071(16)30083-1
25
Jagadeesh Menon, Babu Ram Thapa, Rajni Kumari, Srikanth Puttaiah Kadyada, Satyavati Rana, Sadhna B. Lal. Efficacy of Oral Psyllium in Pediatric Irritable Bowel SyndromeJournal of Pediatric Gastroenterology and Nutrition 2023; 76(1): 14 doi: 10.1097/MPG.0000000000003622
26
Brooks D. Cash, Brian E. Lacy, Tharaknath Rao, David L. Earnest. Rifaximin and eluxadoline — newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Expert Opinion on Pharmacotherapy 2016; 17(3): 311 doi: 10.1517/14656566.2016.1118052
27
Israel Franco, Stephen Cagliostro, Therese Collett-Gardere, Mary Kearins, Paul Zelkovic, Lori Dyer, Edward F Reda. Treatment of Lower Urinary Tract Symptoms in Children With Constipation Using Tegaserod TherapyUroToday International Journal 2010; 3(03) doi: 10.3834/uij.1944-5784.2010.06.17
28
Tina Didari, Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysisWorld Journal of Gastroenterology 2015; 21(10): 3072-3084 doi: 10.3748/wjg.v21.i10.3072
29
Aileen F. Har, Joseph M. B. Croffie. Pediatric Neurogastroenterology2017; : 469 doi: 10.1007/978-3-319-43268-7_44
30
Mark Pimentel, Anthony Lembo, William D. Chey, Salam Zakko, Yehuda Ringel, Jing Yu, Shadreck M. Mareya, Audrey L. Shaw, Enoch Bortey, William P. Forbes. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationNew England Journal of Medicine 2011; 364(1): 22 doi: 10.1056/NEJMoa1004409
31
J. M. Remes‐Troche, M. Torres‐Aguilera, V. Montes‐Martínez, V. A. Jiménez‐García, F. Roesch‐Dietlen. Prevalence of irritable bowel syndrome in caregivers of patients with chronic diseasesNeurogastroenterology & Motility 2015; 27(6): 824 doi: 10.1111/nmo.12556
32
Pier Francesco Almerigi, Mauro Menarini, Gabriele Bazzocchi. Pelvic Floor Disorders2010; : 539 doi: 10.1007/978-88-470-1542-5_74
33
Lynne V McFarland. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008World Journal of Gastroenterology 2008; 14(17): 2625-2629 doi: 10.3748/wjg.14.2625
34
Julie E Stevens, Karen L Jones, Christopher K Rayner, Michael Horowitz. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectivesExpert Opinion on Pharmacotherapy 2013; 14(9): 1171 doi: 10.1517/14656566.2013.795948
35
Yi‐Ling Ye, Huei‐Shin Chang, Yu‐Fang Tseng, Li‐Shian Shi. Suppression of IL‐8 Release by Sweet Olive Ethanolic Extract and Compounds in WiDr Colon Adenocarcinoma CellsJournal of Food Science 2017; 82(8): 1792 doi: 10.1111/1750-3841.13786
36
H. V. Lukyantseva, T. M. Oliinyk, P. V. Kirichek, N. V. Motorna, Yu. P. Luts. MODERN VIEW OF REGULATORY MECHANISMS OF MOTOR FUNCTION OF THE COLON Bulletin of Problems Biology and Medicine 2021; 4(1): 40 doi: 10.29254/2077-4214-2021-4-162-40-46
37
Teita Asano, Ken-ichiro Tanaka, Arisa Tada, Hikaru Shimamura, Rikako Tanaka, Hiroki Maruoka, Mitsuko Takenaga, Tohru Mizushima. Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndromeScientific Reports 2017; 7(1) doi: 10.1038/srep40214
38
T. M. Oliinyk, K. V. Rozova, O. I. Kovalchuk, T. Ya. Raskaliei, V. B. Raskaliei, Yu. K. Khmelnytska. THE PARTICIPATION OF HUMORAL MECHANISMS IN THE REGULATION OF THE CONTRACTILE ACTIVITY OF SMOOTH MUSCLE TISSUE OF THE INTESTINEBulletin of Problems Biology and Medicine 2023; 1(2): 42 doi: 10.29254/2077-4214-2023-4-171-42-47
39
Aileen F. Har, Joseph M. B. Croffie. Pediatric Neurogastroenterology2013; : 441 doi: 10.1007/978-1-60761-709-9_41
40
Teita Asano, Ken-ichiro Tanaka, Shintaro Suemasu, Tomoaki Ishihara, Kayoko Tahara, Toshio Suzuki, Hidekazu Suzuki, Shin Fukudo, Tohru Mizushima. Effects of β-(1,3–1,6)-d-glucan on irritable bowel syndrome-related colonic hypersensitivityBiochemical and Biophysical Research Communications 2012; 420(2): 444 doi: 10.1016/j.bbrc.2012.03.015
41
Kristin A. Zernicke, Tavis S. Campbell, Philip K. Blustein, Tak S. Fung, Jillian A. Johnson, Simon L. Bacon, Linda E. Carlson. Mindfulness-Based Stress Reduction for the Treatment of Irritable Bowel Syndrome Symptoms: A Randomized Wait-list Controlled TrialInternational Journal of Behavioral Medicine 2013; 20(3): 385 doi: 10.1007/s12529-012-9241-6